Related Experiment Video
Updated: Jul 3, 2026
05:56
Exploring Caspase Mutations and Post-Translational Modification by Molecular Modeling Approaches
Published on: October 13, 2022
A novel role for a familiar protein in apoptosis induced by proteasome inhibition
1Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. dmcconke@mdanderson.org
Cancer Cell
|July 5, 2008
Abstract:
In this issue of Cancer Cell, Nickeleit et al. (2008) identify a new proteasome inhibitor, argyrin A, and show that it induces apoptosis and inhibits angiogenesis via p27-dependent mechanisms. Their observations challenge current thinking about how this class of promising cancer therapies works and why they selectively kill cancer cells.
Insights
Researchers discovered argyrin A, a novel proteasome inhibitor, that triggers cancer cell death (apoptosis) and blocks blood vessel growth (angiogenesis) through p27-dependent pathways. This finding offers new insights into cancer therapy mechanisms.
Area of Science:
- Molecular oncology
- Cancer biology
- Drug discovery
Background:
- Proteasome inhibitors represent a promising class of cancer therapeutics.
- The precise mechanisms underlying their selective toxicity to cancer cells and their broader effects, such as anti-angiogenesis, are not fully elucidated.
- Understanding these mechanisms is crucial for optimizing cancer treatment strategies.
Discussion:
- Nickeleit et al. identify argyrin A, a new proteasome inhibitor.
- Argyrin A induces apoptosis (programmed cell death) in cancer cells.
- It also inhibits angiogenesis (formation of new blood vessels), a critical process for tumor growth.
Key Insights:
- The action of argyrin A is mediated through p27-dependent pathways.
- This finding challenges existing models of proteasome inhibitor function.
- The study sheds light on the selective killing of cancer cells by this drug class.
Outlook:
- Argyrin A represents a potential new therapeutic agent for cancer treatment.
- Further research into p27-dependent mechanisms could lead to more effective cancer therapies.
- This work may guide the development of next-generation proteasome inhibitors.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
01:17The Extrinsic Apoptotic Pathway
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
01:24Caspases
Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside cells.
01:30Apoptosis
Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size reduction of the tissue.
01:13The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
02:18The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...